Shanghai Bangyao Biotechnology Co., Ltd. - BioRay Laboratories

Clinical Roundup: Gene-Edited Therapies for Beta...

Jul. 26, 2023

In this roundup, we provide a summary of the ongoing gene-editing trials for beta thalassemia. This update includes trials sponsored by Vertex...

Clinical Trial Update: Gene-edited CAR T Therapies

Mar. 17, 2021

This week’s clinical update looks at 3 clinical trials for CRISPR-edited CAR T therapies for the treatment of B-cell cancers or multiple myeloma.

CRISPR Clinical Trial Update – Beta Thalassemia

Mar. 10, 2021

This week’s clinical update looks at two clinical trials for beta thalassemia using CRISPR-Cas9-edited donor-derived haematopoeitic stem cells (HSCs).

Shanghai Bangyao Biotechnology Co., Ltd. - BioRay Laboratories

Sickle Cell Disease, SCD, (NCT06287099)
Sponsors:
Bioray Laboratories

IND Enabling

Phase I

Phase II

Phase III

Transfusion-dependent Beta-thalassemia, TDT, (NCT06298630)
Sponsors:
Bioray Laboratories

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Autoimmune Diseases, (NCT05859997)
Sponsors:
Bioray Laboratories

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT06300723)
Sponsors:
Bioray Laboratories

IND Enabling

Phase I

Phase II

Phase III

Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05577312)
Sponsors:
Bioray Laboratories

IND Enabling

Phase I

Phase II

Phase III

Beta-Thalassemia, BT, (NCT05442346)
Sponsors:
Bioray Laboratories

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT05308875)
Sponsors:
Bioray Laboratories

IND Enabling

Phase I

Phase II

Phase III

Castration-Resistant Prostate Cancer, CRPC, (NCT04768608)
Sponsors:
Zhejiang University

IND Enabling

Phase I

Phase II

Phase III